1Global Leading Technology and Platform Advantages

• • Proprietary Antibody Engineering Platform (FBDB™)
    • Developed one of the industry’s leading high-affinity, multifunctional, and highly specific fusion proteins (mono-, bi-, and tri-functional).
    • Differentiated design strategy that effectively reduces immune-related adverse effects while significantly enhancing tumor-target specificity and binding affinity.
  • Highly scalable technology: The platform supports multiple globally competitive pipelines and future partnerships/licensing opportunities, serving as a key engine for long-term value creation.

2.Diverse and High-Potential R&D Pipeline

• Flagship product HCB101: One of the few CD47-targeting broad-spectrum anti-cancer biologics progressing into clinical trials across China, the United States, and Taiwan, demonstrating strong global competitiveness.
• Next-generation innovative pipelines (e.g., HCB301): Received regulatory approvals in both China and the United States. The program covers multiple tumor types and immune mechanisms, highlighting the platform’s multi-indication potential.
• Advancing tri-functional biologics (e.g., HCB303, HCB302): Continued development of tri-functional candidates is accelerating clinical progress and driving breakthrough therapeutic potential.
• Significant combination therapy potential: Fusion biologics enable differentiated therapeutic advantages and align with global trends in immuno-oncology combination strategies.

3.International Expansion and Collaboration Potential

• R&D and multi-center clinical sites across Taiwan, the U.S., and China:
  By combining Taiwan’s strong R&D capabilities with clinical deployment in the U.S., China, and Taiwan, HanchorBio is well-positioned to conduct multinational trials and accelerate market expansion.
• High international visibility:
  The company actively participates in leading global conferences such as CSCO and SITC, strengthening brand credibility and international recognition.
• Future licensing and strategic partnerships:
  HanchorBio possesses the capabilities and flexibility to engage in BD and licensing transactions with global pharmaceutical companies.

4.Clear and Achievable Growth Milestones

• Rapid corporate development:
  Since its founding in 2020, HanchorBio has completed multiple financing rounds (from Pre-A to Series B) and successfully listed on Taiwan’s Emerging Stock Board in June 2025, receiving strong recognition from the capital markets.
• Leading R&D efficiency:
  The company has advanced from preclinical to clinical development in an average of only 2.3 years, demonstrating exceptional execution capability and development efficiency.
• Global patent portfolio:
  With more than 95 patents filed globally, HanchorBio continues to strengthen its intellectual property moat and enhance long-term competitive advantage.

5.Experienced Executive and R&D Teams

• Proven founder track record:
  The founder is a second-time entrepreneur, with the first company successfully listed on the Hong Kong A-share market and achieving a market capitalization of NT$15 billion.
• International-caliber executive team:
  HanchorBio’s C-level leaders possess extensive international experience across the United States, Europe, Singapore, and other major biopharma markets, spanning both scientific and managerial functions.
• R&D team with successful drug-launch experience:
  The Taiwan-based R&D team previously advanced its first biologic from preclinical development through clinical stages to commercial launch, now serving patients across China, Southeast Asia, and Europe.

6.Investment Value Proposition

• High technological barriers × global clinical footprint → strong potential for acquisition or licensing by major pharmaceutical companies.
• Clinical data will be the next major value catalyst, driving the company’s upcoming inflection points.
• Limitless potential as a platform-based company → offering both single-asset breakthrough opportunities and long-term expansion across a diversified biologics pipeline.